Advertisement
Advertisement
U.S. Markets open in 6 hrs 59 mins
Advertisement
Advertisement
Advertisement
Advertisement

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.05-0.23 (-2.24%)
At close: 04:00PM EDT
9.85 -0.20 (-1.99%)
After hours: 07:45PM EDT
Advertisement
Sign in to post a message.
  • J
    John
    $SRNE conversation
    Jay: "I would ask everyone respectfully to stop bullying Ariadinvestor. He is not short and do not bully anyone unless you start bothering him first. He just like one of us true long. It just breaks uniformity. And there is nothing you can do about him." @Jay This post of yours has been deleted. So I am copying and pasting it to both the $SRNE board and the $AUPH board.
    Bullish
  • A
    Ariadinvestor
    Mark shorted @ $23 right before AUPH surged to $33+. I congratulated him on Nov 03 => Mark shorted @ $23.👍 Congratulations! Short squeeze can cure his HPD due to which, Mark seeks attention by shouting/bragging "Watch and learn...I haven't missed a call yet. I made a killing! I made a killing. A killing and a killing I made ..."🤣 <= I congratulated Mark this way repeatedly on Nov. 3 on this public forum. cc: $srne
    Bullish
  • J
    JP
    Ariandinvestor takes Colon blow
  • D
    Darren
    I’m in for 2000 shares in the morning, everyone take a deep breath as we reverse up😊. Gonna happen
  • B
    Big Toe
    Futures Red again smh ..
  • J
    Jon
    $SRNE conversation
    Ariadinvestor claims he does not attack anyone unless he has been attacked first. TRUE! frankie C has resurfaced and resumed her attacks. Doug is an new attacker. Wayne, Ray, David, nunu, Big Toe & Yahoo Admin Todd/T/jim never stop their attacks. We can find THE TRUTH by switching to "Newest Reactions". Ariadinvestor counterattacks the attackers. When will the war end?

    "
    cc: $AUPH $SRNE $auph $srne
    ---------------
    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    Aug 26, 2021 (AB Digital via COMTEX) -- VICTORIA, British Columbia - Aurinia Pharmaceuticals (NASDAQ: $AUPH ) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma behemoth. The leading pharmaceutical company is in talks with AUPH for an acquisition pegged at $35 per American Depositary Share (ADS) or plus.

    On paper, the total consideration of the acquisition is estimated to come up to $4,485 billion in the form of $35 in cash ordinary shares or plus. The transaction has been said to be unanimously approved by the Board of Directors of both companies and is expected to close in the third quarter of 2021.

    “This collaboration will help us pave the way to create many more solutions in the autoimmune space and will be able to increase our marketing process” said Peter Greenleaf, President and Chief Executive Officer of Aurinia Pharmaceuticals speaking about the said merger.

    Founded in 2012, Aurinia Pharmaceuticals Inc specializes in principled drug development and commercialization in the field of autoimmune diseases. The Canadian company’s stocks are currently valued at $14.33 (as of 23 August 2021), and the values are projected to rise with the impending acquisition.

    With a market cap of $2 billion, the Company packs a lot of potential for its original solutions in the field of autoimmune diseases. The merger would come as the perfect progression to the acquiring company that is known to cashing in on strong trends to make deals of economic relevance.

    Various sources and market whispers indicated that multiple pharma companies were keen on exploring acquisition opportunities with $AUPH . However, this market leader was finally the one that converted these interests through its proposal of a tuck-in acquisition.

    Earlier this year, the acquiring company also made investments in the space of oncology. After having spent roughly $1.4 billion in milestone payments the pharma giant was exploring other investments in non-linear pharma fields. AUPH emerged as one of the safest buys on its list.

    As per this proposal, the acquisition indicates a merger of the two companies. Even though the acquiring company is capable of deploying a windfall of cash, a tuck-in acquisition seems ideal for the current market. AUPH has presented itself as the perfect option for the acquiring company to leverage the company’s skills and knowledge.

    The merger will also help $AUPH bring its deep experience in actively pursuing a broader portfolio of innovative drugs for autoimmune diseases like Lupus and Nephritis to the table. A successful tuck-in acquisition can increase revenues and broaden the acquiring company's capabilities and resources, which can effectively boost AUPH’s growth graph.

    The Company launched its first product Lupkynis in January this year. The drug that was made to treat Lupus Nephritis clocked in revenues of $6.6 million in the second quarter superseding pre-launch expectations. $SRNE short squeeze ?

    Recently the company also acquired novel pipeline assets targeting autoimmune and kidney-related diseases diversifying its portfolio of offering therapeutic solutions to people living with rare diseases.

    Once the merger with the market leader goes through, AUPH is expected to bring promising new products to the market keeping up with its offerings in the space of autoimmune diseases.

    About Aurinia

    Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

    Statutory Statement
    $SRNE
    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including statements regarding the underwritten public offering, the amount and anticipated use of proceeds from the offering, those relating to Company's product development, clinical and regulatory timelines, market opportunity, competitive
    Bullish
  • A
    Ariadinvestor
    $SRNE conversation
    @T/Todd/jim ✔"History repeats itself. Both you & I are repeating the Ariad war. I won it as Ariad’s science & pipeline eventually won. I will also win the $AUPH / $SRNE wars as time will let you know it. Will you declare defeating me again by abusing your Yahoo Admin power & deleting my posts/accounts? You’ve left tons of evidences for Verizon to get sued. You don't care about losing your 1st job as a Yahoo Admin because you get paid more from your 2nd job as a paid basher, right? Didn't you say ARIA would drop to $2 & bankrupt right before the $24 buyout?" I've been posting this since 7/5/19.
    Bullish
  • S
    Singer
    Almost a year since the August 2021 leak….
    Bullish
  • T
    T
    $srne and $auph stock price is going down hard, while Ariad/linda/john./jon is posting more messages for her own enjoyment. She does enjoy the stock going down.
  • T
    T
    $srne and $auph stock price is going down hard, while Ariad/linda/john./jon is posting more messages for her own enjoyment. She does enjoy the stock going down.
    Bearish
  • C
    Cindy
    thanks motley
  • s
    sharon
    AIMT was bought out when the stock was at the bottom of its trading range @10 dollars and when biotech was selling off ~~ Nestle bought AIMT for $37 when the stock was trading at $10......Lupkynis is for sale while investors are waiting for profits!! go go go ~~
  • M
    Martin
    buy more!
  • T
    Tinny
    Last night scrolled back IMMU board on ST beyond 9/14/20. It went down horribly low near 9 and then catalysts came,took it to 30s and 40s and then BO at 88. Two catalysts here upcoming EMA and patent settlement. Nothing gonna happen overnight. We won't get 52$ in any long weekend. Looks like we will have to wait for SP to reach 16-20 by positive catalysts first.
  • C
    Cindy
    management can't find a buyer now
  • K
    Kurt
    Published on June 27th

    Capital Investment Advisors LLC Boosts Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
  • C
    Cindy
    sub $5 soon
  • J
    Jack
    it was not enough to lose all day but ah really?
  • K
    Kurt
    It’s so strange how AUPH has gone dark on communications. They are waiting for EU approval, an Otsuka milestone payment, Sun litigation to settle, etc. Plus, they hired Westwicke for IR (which specializes in M&A). All of this points to some kind of BO discussions going on behind closed doors.
  • D
    Dan
    Anyone wanna comment on the large amount of way out of the money calls for July 15th? Just gamblers being gamblers? People betting word of CHMP approval will come before the CHMP meeting?
Advertisement
Advertisement